Canaccord Genuity Maintains Buy on Castle Biosciences, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 53.9%

Neg 53.9% Neu 0% Pos 0%

Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $50 to $40.